Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics
Roche's Q1 2026 sales grew 6% at constant exchange rates, driven by strong demand for innovative medicines, particularly in multiple sclerosis and oncology.
Asset / Drug
Drug and asset intelligence for fenebrutinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
BTK Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.